Abstract:Alpha-synuclein (α-syn), as a highly soluble presynaptic protein expressed in the brain, plays an important role in recycling synaptic vesicles and regulating the synthesis, storage, and release of neurotransmitters. Accumulation of α-syn in Lewy bodies and Lewy neurites is the pathological hallmark of Parkinson's disease (PD), so inhibition of α-syn aggregation may provide a novel approach for treating PD. In this study, the 3D structure of α-syn was downloaded from Protein Data Bank (PDB ID: 2N0A). A ligand-based pharmacophore model was conducted on a set of 43 diverse α-syn ligands, and the results suggested that two hydrogen-bond acceptors, one hydrophobic group, and two aromatic rings were significant to the inhibition of α-syn aggregation. A ligand-based 3D-QSAR model was also established with good statistical significance (R2 = 0.920) and excellent predictive ability (Q2 = 0.752). Novel indolinone derivatives were designed and synthesized based on the pharmacophore model. Subsequently, the 3D-QSAR model was used to predict the inhibitory activities towards α-syn aggregation, and the actual inhibitory activities were evaluated by thioflavin-T assay in vitro with the best inhibitory activity reaching 45.08%. The fitting results indicated that the built pharmacophore and 3D-QSAR models provided better reliability and accuracy for compound modification and prediction of the activity thereof. A ligand-based pharmacophore modeling and 3D-QSAR study have been performed on a set of 43 diverse ligands for α-synuclein for the first time. Based on the best pharmacophore modeling, novel indolinone derivatives were designed and synthesized, and the inhibitory activities for α-synuclein aggregation were evaluated by thioflavin-T assay in vitro, which preliminary indicated that five pharmacophore sites (two hydrogen bond acceptors (A), a hydrophobic group (H), and two aromatic rings (R)) in compounds contribute to the inhibitory activities. In the study, the built pharmacophore modeling and 3D-QSAR provided better reliability and accuracy for compound modification and prediction of the activity thereof.

In silico study on graphene quantum dots modified with various functional groups inhibiting α‑synuclein dimerization

Graphene quantum dots prevent alpha-synucleinopathy in Parkinson's disease

Graphene-Based Nanoparticles as Potential Treatment Options for Parkinson's Disease: A Molecular Dynamics Study

Destabilization of Human Islet Amyloid Polypeptide Fibrils by Charged Graphene Quantum Dots: A Molecular Dynamics Investigation with Implications for Nanomedicine

Graphene quantum dots for the inhibition of β amyloid aggregation.

Inhibition of Α‐synuclein Fibrillization by Dopamine Analogs Via Reaction with the Amino Groups of Α‐synuclein

Halogen doped graphene quantum dots modulate TDP-43 phase separation and aggregation in the nucleus

Synergistic Inhibitory Effect of GQDs-Tramiprosate covalent binding on amyloid Aggregation.

Adsorption Mechanism of Amyloid Fibrils to Graphene Nanosheets and Their Structural Destruction

Investigating the Theranostic Potential of Graphene Quantum Dots in Alzheimer's Disease

Inhibition of α-Synuclein Misfolding into β-Sheet Domains on Medium-Sized Gold Nanoclusters: Evidence from Enhanced Sampling MD Simulations

Catechol‐induced covalent modifications modulate the aggregation tendency of α‐synuclein: An in‐solution and in‐silico study

Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability

Pharmacophore Modeling and 3D-QSAR Study for the Design of Novel Α-Synuclein Aggregation Inhibitors.

Hybrids of polyphenolic acids and xanthone, the potential preventive and therapeutic effects on PD: Design, synthesis, in vitro anti-aggregation of α-synuclein, and disaggregation against the existed α-synuclein oligomer and fibril

Naphthoquinone–dopamine Hybrids Disrupt Α-Synuclein Fibrils by Their Intramolecular Synergistic Interactions with Fibrils and Display a Better Effect on Fibril Disruption

Graphene Quantum Dots Modulate Stress Granule Assembly and Prevent Abnormal Phase Transition of Fused in Sarcoma Protein

Co-aggregation of α-synuclein with Amyloid-β Stabilizes β-sheet-rich Oligomers and Enhances the Formation of β-barrels

Pyrazolamide derivatives inhibit α-Synuclein aggregation, disaggregate preformed fibers, and reduce inclusion formation in neuron cells

O-GlcNAcylation Inhibits the Oligomerization of Alpha-Synuclein by Declining Intermolecular Hydrogen Bonds Through a Steric Effect.

Molecular Dynamics Simulations Reveal the Mechanism of Graphene Oxide Nanosheet Inhibition of Aβ1-42 Peptide Aggregation.